Search

Home > GRACEcast Lung Cancer Video > Adding to Tarceva in a Broad NSCLC Population: Weighing Benefits with Risks
Podcast: GRACEcast Lung Cancer Video
Episode:

Adding to Tarceva in a Broad NSCLC Population: Weighing Benefits with Risks
Category: Science & Medicine
Duration: 00:02:58
Publish Date: 2015-07-05 14:00:00
Description:

A trial comparing Tarceva (erlotinib) to Cometriq (cabozantinib) showed modest benefit for EGFR wild type patients, but the challenging side effect profile should lead us to question if we can identify only patients most likely to benefit from Cometriq.
Total Play: 0